Vol. 22/No. 14 | OncologyLive

Emerging Therapies Expand Options in Lung Cancer

July 23, 2021

Cover Story

During the past 12 months, the treatment landscape for patients with non–small cell lung cancer has expanded dramatically with FDA approvals of the first drugs directed at KRAS G12C and EGFR exon 20 mutations as well as continued progress in developing new therapies for subsets of patients with other molecularly targetable alterations and with PD-L1–high disease.

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off

July 16, 2021

The lead novel candidate, the WEE1 inhibitor adavosertib, has been tested in more than 50 completed or ongoing clinical studies but has yet to proceed to a phase 3 trial despite showing promising safety and efficacy as monotherapy and in combination with a range of other cancer therapies.

Gaps Persist in Understanding the Fundamentals of Informed Consent

July 14, 2021

Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.